Quarterly ResultAug 6, 2026, 04:08 PM
Apyx Medical Q2 Revenue $13.9M, Surgical Aesthetics +28%
AI Summary
Apyx Medical reported strong second-quarter 2026 financial results, with total revenue increasing 22% to $13.9 million, primarily driven by a 28% growth in its Surgical Aesthetics segment. The company also significantly reduced its net loss to $3.2 million and narrowed its Adjusted EBITDA loss to $0.7 million. Operational highlights include expanded FDA 510(k) clearance for the AYON Body Contouring System and a successful limited launch of its power liposuction handpiece. Apyx Medical reaffirmed its full-year 2026 total revenue guidance of $59.0 million to $60.0 million.
Key Highlights
- Total revenue for Q2 2026 increased 22% to $13.9 million, up from $11.4 million in Q2 2025.
- Surgical Aesthetics segment revenue grew 28% to $12.4 million in Q2 2026.
- Net loss attributable to stockholders improved to $3.2 million in Q2 2026 from $3.8 million in Q2 2025.
- Adjusted EBITDA loss significantly narrowed to $0.7 million in Q2 2026 from $2.0 million in Q2 2025.
- Reaffirmed total revenue guidance for FY2026 in the range of $59.0 million to $60.0 million.
- Received expanded FDA 510(k) clearance for the AYON Body Contouring System to include power liposuction.
- Commenced a limited commercial launch of the reusable power liposuction handpiece for the AYON platform.
- Cash and cash equivalents stood at $27.6 million as of June 30, 2026.
Price Impact
More from APYX